Welcome to our dedicated page for Betterware Mex SEC filings (Ticker: BWMX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
From stackable kitchen bins to JAFRA fragrances, Betterware de Mexico (BWMX) moves millions of items through a vast distributor network鈥攁nd those operations leave a distinct trail in the company鈥檚 SEC disclosures. If you鈥檙e searching for Betterware de Mexico insider trading Form 4 transactions or need Betterware de Mexico SEC filings explained simply, this page is your starting point.
Every document is available the moment it appears on EDGAR, and our AI-powered summaries translate peso conversions and distributor metrics into clear insights. Whether you need the Betterware de Mexico quarterly earnings report 10-Q filing, are comparing compensation in the Betterware de Mexico proxy statement executive compensation section, or checking a sudden supplier update in an 8-K, we connect each form to the real questions investors ask.
- 10-K 鈥� Betterware de Mexico annual report 10-K simplified: segment revenue, distributor counts, currency exposure.
- 10-Q 鈥� Betterware de Mexico earnings report filing analysis with quarter-over-quarter growth and margin shifts.
- Form 4 鈥� Betterware de Mexico Form 4 insider transactions real-time, spotlighting Betterware de Mexico executive stock transactions Form 4.
- 8-K 鈥� Betterware de Mexico 8-K material events explained, covering JAFRA launches, distribution milestones, or financing updates.
Set custom alerts, export tables, and compare trends鈥�understanding Betterware de Mexico SEC documents with AI lets you monitor working-capital swings, track inventory turns, and catch market-moving data before the crowd.
NCSM鈥檚 Q2-25 10-Q shows a clear YoY turnaround. Revenue rose 23% to $36.5 mm, driven by a 46% jump in product sales that offset an 19% decline in service revenue. Consolidated gross profit improved $2.5 mm and the operating loss narrowed to $2.0 mm from $4.2 mm. A $1.0 mm deferred-tax benefit plus FX gains lifted net income attributable to NCS to $0.9 mm ($0.34 diluted EPS) versus a $3.1 mm loss (-$1.21) last year.
For the six months, revenue climbed 18% to $86.5 mm and net income swung to $5.0 mm ($1.84 diluted EPS). Canada contributed 49% of Q2 sales, the U.S. 37%, and other markets 14%.
Balance sheet. Cash remained healthy at $25.4 mm; NCS drew no amounts on its $35 mm ABL facility. Total debt consists solely of $7.7 mm of finance leases. Equity increased to $124.0 mm.
Cash flow. H1 operating cash inflow fell to $1.9 mm from $4.1 mm on higher working-capital needs; capex was modest at $0.7 mm.
Strategic update. On 31-Jul-25 NCS closed the $5.9 mm cash acquisition of Reservoir Metrics to expand tracer diagnostics, with an earn-out of up to $1.3 mm.
Risks & Outlook. Management cites stable Canadian activity, softer U.S. completions, potential international growth, and cost headwinds from steel/chemical tariffs. Ongoing Canadian patent appeals and U.S. litigation could affect future results but no gain/loss has been booked.
GT Biopharma (GTBP) filed an 8-K summarizing the results of its 24 Jul 2025 annual meeting. 58.9% of the 3.15 M outstanding shares were represented.
- Board elections: All four director nominees鈥擬ichael Breen, Charles Casamento, Hilary Kramer and David C. Mun-Gavin鈥攚ere re-elected; support ranged 98.8-99.0% of votes cast, with 658.5 k broker non-votes.
- Auditor: Weinberg & Company, P.A. was ratified for FY-25 (96.8% FOR).
- Say-on-pay: Advisory approval of executive compensation passed with 97.3% FOR.
- Nasdaq Rule 5635 share issuance: Shareholders approved the potential issuance of 鈮�19.99% of common stock related to May 2025 financing agreements (97.3% FOR), enabling conversion of Series L 10% Preferred and exercise of associated warrants.
- Incentive plan: Amendment adding 583,334 shares to the 2022 Omnibus Incentive Plan passed (96.0% FOR).
No earnings data were provided. All proposals passed comfortably, clearing governance and capital-raising hurdles but creating potential dilution if convertible securities and warrants are exercised.
FAQ
What is the current stock price of Betterware Mex (BWMX)?
What is the market cap of Betterware Mex (BWMX)?
What is Betterware Mex's core business?
How does Betterware Mex generate revenue?
What are the main product segments of Betterware Mex?
How does the direct selling model benefit Betterware Mex?
In what ways does the JAFRA segment contribute to the business?
How has Betterware Mex positioned itself in the competitive landscape?
What geographical areas does Betterware Mex serve?
How does Betterware Mex ensure product quality and innovation?
